Results
In-person events
Out-of-Office Live
Speaker:
Katie Murray, DO, MS, FACS
Davio's Lynnfield, 1250 Market Street, Lynnfield, MA 01940
Description:
Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.
Out-of-Office Live
Speaker:
Ravi Chauhan, MD
Augustino's Italian Eatery, 2 10th Street, Augusta, GA 30901
Description:
Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.
Out-of-Office Live
Speaker:
Katie Murray, DO, MS, FACS
Aspen Grille, 5101 N Kings Hwy, Myrtle Beach, SC 29577
Description:
Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.
Out-of-Office Live
Speaker:
Dana Moore, MBA, MPH
Westin Annapolis, 100 Westgate Cir, Annapolis, MD 21401
Description:
Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.
Out-of-Office Live
Speaker:
Katie Murray, DO, MS, FACS
Fushimi Times Square, 311 W 43rd Street, New York, NY 10036
Description:
Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.
Out-of-Office Live
Speaker:
Ravi Chauhan, MD
Chamberlain's Steak & Fish, 5330 Belt Line Road, Dallas, TX 75254
Description:
Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.
Out-of-Office Live
Speaker:
Katie Murray, DO, MS, FACS
Sullivan's Steakhouse, 1928 South Blvd., Charlotte, NC 28203
Description:
Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.
Out-of-Office Live
Speaker:
Lambros Stamatakis, MD
Mix Prime, 757 Main St, Woodbury, CT 06798
Description:
Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.
Out-of-Office Live
Speaker:
Ravi Chauhan, MD
Victors, 126 W Evans St, Florence, SC 29501
Description:
Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.
Out-of-Office Live
Speaker:
Aaron Berger, MD
Waldorf Astoria Orlando, 14200 Bonnet Creek Resort Lane, Orlando, FL 32821
Description:
Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.
Online events
Hybrid (Speaker Remote)
Speaker:
Katie Murray, DO, MS, FACS
Location:
Hyde Park Prime Steakhouse, 100 N Atlantic Avenue, Daytona Beach, FL 32118
Description:
Please join us for an interactive discussion on the role of ADSTILADRIN® in managing patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). During this discussion, we’ll introduce ADSTILADRIN and explain its mechanism of action, review clinical trial data showing the safety and efficacy of ADSTILADRIN, and finally, discuss practical considerations that may help facilitate the successful implementation of ADSTILADRIN into clinical practice.